Results with new bioresorbable stent (BRS) technologies reported at EuroPCR 2017

May 19, 2017

Paris, France: Promising results were reported in late-breaking trials with novel bioresorbable stent technologies at EuroPCR 2017, paving the way for ongoing developments in stents that are dissolved or reabsorbed after achieving vessel expansion in percutaneous coronary intervention procedures.

Researchers reported results with seven bioresorbable stent technologies:

Results from the prospective multicentre RENASCENT II study of the Amaranth Medical APTITUDE BRS stent, a novel ultra-high molecular weight poly-L-lactide BRS with a new, thinner strut (120 μm), reported no events at one year in 60 patients treated for single lesion coronary artery stenosis. Coronary artery imaging with optical coherence tomography (OCT) demonstrated excellent wall apposition and full, homogenous endothelial wall coverage, with no valleys and peaks between regions with struts and those without struts. "The results are very positive. The scaffold delivers a very low medium-term event rate and the stent favours good laminar flow in blood vessels," said lead author Antonio Colombo, from San Raffaele Scientific Institute, Milan, Italy, although he cautioned that the study was small.

The key imaging results from the DESolve Nx Study, a prospective registry including 126 patients, showed a mean lumen gain of 9% at six months, as measured by intravascular ultrasound (IVUS), and an angiographic late luminal loss (LLL) of 0.2mm. "This is a clinical breakthrough as no other BRS technology has been successful in achieving such impressive results and, at the same time, degrading in six months with near complete resorption (mass loss) in one year," said lead author Stefan Verheye, from ZNA Middelheim, Antwerpen, Belgium. He added that the 18-month and 36-month imaging data showed sustained efficacy and confirmed the degradation and complete resorption (mass loss) in one year. There were no late or very late definite or probable scaffold thromboses and no target lesion revascularisations from years two to four. Verheye concluded, "Early degradation and early resorption is not only an intuitive wish, it is a must for a BRS technology in order to succeed. Companies attempted but failed to achieve clinical effectiveness, primarily due to chronic recoil of their scaffolds. In an effort to resolve this issue, companies had to revert to much longer degradation and resorption profiles. The Elixir DESolve scaffold is the only technology to date to resolve the chronic recoil issue, as evidenced by the Nx trial data."

One-year results from the first-in-man MeRes-1 study of the safety and efficacy of the novel MeRes 100 scaffold in 108 patients with 116 de novo coronary artery lesions showed that the composite endpoint of cardiac death, myocardial infarction (MI) and ischaemia-driven target lesion revascularisation (ID-TLR) occurred in one patient (0.93%). There was no scaffold thrombosis. One-year computed tomography (CT) angiography demonstrated that all scaffolds were patent. Six-month quantitative coronary angiography showed a low rate of late lumen loss and no restenosis. Intravascular ultrasound and OCT analyses also gave favourable results, reported Ashok Seth, from Fortis Escort Heart Institute, New Delhi, India. He said, "The positive results of this study provide the basis for a larger, randomised trial against a second-generation metallic drug-eluting stent."

Data were also reported for the following studies, but results were not available to include in the press release:
Contact information

Antonio Colombo
San Raffaele Scientific Institute
Milan, Italy

Stefan Verheye
ZNA Middelheim
Antwerpen, Belgium

Ashok Seth
Fortis Escorts Heart Institute
New Delhi, India

Michael Haude
Städtische Kliniken Neuss
Lukaskrankenhaus GmbH
Neuss, Germany

Alexandre Abizaid
Instituto Dante Pazzanese
Sao Paulo, Brazil

Xu Bo
Fu Wai Hospital
Beijing, China

Corresponding session

EuroPCR 2017 session: Tuesday 16 May 12.00-13.30, Hot Line/Late-breaking Trials, Coronary Interventions, Stents and Scaffolds; Room 351

Help for journalists to cover EuroPCR 2017
For any press-related inquiries, please contact:

EuroPCR Press Coordinator, Isabelle Uzielli

Register and attend EuroPCR 2017 as a journalist
Press registration for EuroPCR is open to accredited journalists, free of charge.
Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to

EuroPCR press releases
EuroPCR press releases can be found at

Attend press briefings
For the press briefing schedule check

EuroPCR abstracts
Abstracts are available online at

Notes to Editors
What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 11,500 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Milan Italy, Chengdu China and Tokyo Japan.

For further information on EuroPCR, PCR London Valves, PCR Peripheral, PCR-CIT China Chengdu Valves, GulfPCR-GIM, AsiaPCR, AfricaPCR, PCR Tokyo Valves, and all PCR activities, please contact: Célia Vilà:

For more information, please visit: and follow us on Twitter using the hashtag #EuroPCR


Related Coronary Artery Disease Articles from Brightsurf:

Researchers use multi-ancestry comparison to refine risk factors for coronary artery disease
An international group led by researchers from the RIKEN Center for Integrative Medical Sciences have used a combination of genome-wide association analysis--or GWAS--and a trans-ancestry comparison of different GWAS studies, to come up with a more accurate predictor of coronary artery disease based on genetic factors.

Oral radiography can reveal chronic coronary artery disease
A study found a link between carotid artery calcification observable in radiographs and coronary artery disease as well as several oral infections.

A new strategy to counter insulin damage in coronary artery disease
By studying blood vessel tissue from 674 patients, a research team has discovered how insulin contributes to the dysfunction of blood vessels in atherosclerosis, one of the most common chronic health conditions worldwide.

3D fusion imaging improves coronary artery disease diagnosis
A new technique that combines CT and MRI can bolster coronary artery disease diagnosis and help to define appropriate treatment for patients suffering from the disease, according to a new study.

Associations between vaspin levels and coronary artery disease
In a new publication from Cardiovascular Innovations and Applications; DOI, Lutfu Askin, Okan Tanriverdi, Hakan Tibilli and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider associations between vaspin levels and coronary artery disease.

Waist size, not body mass index, may be more predictive of coronary artery disease
For years, women have been told that weight gain could lead to heart disease.

Women with coronary artery wall thickness at risk for heart disease
The thickness of the coronary artery wall as measured by MRI is an independent marker for heart disease in women, according to a new study.

SPIE journal reports advances in use of 3D models in assessing coronary artery disease
In an article published in SPIE's Journal of Medical Imaging (JMI), researchers announce critical advances in the use of 3D-printed coronary phantoms with diagnostic software, further developing a non-invasive diagnostic method for Coronary Artery Disease (CAD) risk assessment.

E-cigarettes linked to heart attacks, coronary artery disease and depression
Concerns about the addictive nature of e-cigarettes -- now used by an estimated 1 out of 20 Americans -- may only be part of the evolving public health story surrounding their use, according to data being presented at the American College of Cardiology's 68th Annual Scientific Session.

Is guideline-recommended therapy for coronary artery disease more likely in Medicare Advantage?
Medicare Advantage is Medicare's managed-care alternative to traditional fee-for-service Medicare.

Read More: Coronary Artery Disease News and Coronary Artery Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to